Myasthenic Crisis Management
Myasthenic crisis (MC) is a life-threatening complication of myasthenia gravis (MG) defined by respiratory insufficiency severe enough to require invasive mechanical ventilation or noninvasive ventilatory support. MC occurs in approximately 15–20% of patients with MG, usually within the first 2–3 years of the disease course. The mortality of MC in contemporary practice is less than 5% with prompt recognition and aggressive ICU management, although it can reach 10–12% in cohorts with significant comorbidities. Impending crisis — a rapid escalation in myasthenic weakness that threatens respiratory failure within days to weeks — demands the same urgency of evaluation and intervention.
Bottom Line
- Definition: Respiratory failure from MG requiring intubation or noninvasive ventilation; impending crisis denotes rapid worsening that could lead to respiratory failure within days
- Epidemiology: Affects ~15–20% of MG patients; most common in the first 2–3 years and in patients with thymoma, MuSK antibodies, or prior crisis history
- Triggers: Infection (especially pulmonary) is the most common trigger; no trigger identified in 30–40% of cases
- Respiratory monitoring: Serial FVC and NIF measurements; the 20/30/40 rule (FVC <20 mL/kg, NIF <–30 cmH2O, MEP <40 cmH2O) guides ICU admission and escalation of care
- Immunotherapy: Plasma exchange (PLEX) and IVIg are equally effective first-line rescue therapies; PLEX may have a faster onset of action and is preferred in MuSK MG
- Intubation: Plan for elective intubation based on clinical trajectory rather than waiting for respiratory arrest; avoid succinylcholine; use non-depolarizing agents cautiously
- Prognosis: Median ventilation duration is 12–13 days; most patients can be weaned within 1 month; mortality <5% with modern ICU care
Definition and Classification
Myasthenic crisis reflects respiratory failure due to severe weakness of respiratory muscles (diaphragm and intercostals) and oropharyngeal muscles that maintain a patent upper airway clear of secretions. Two categories are recognized:
- Manifest myasthenic crisis: Severe myasthenic weakness requiring endotracheal intubation with mechanical ventilation or noninvasive positive-pressure ventilation (BiPAP). Routine perioperative care is excluded from this definition.
- Impending myasthenic crisis: Rapid increase in myasthenic weakness that could lead to a crisis within days to weeks. These patients require ICU admission for close monitoring and urgent immunotherapy.
Signs of impending crisis include severe bulbar weakness with inability to handle oropharyngeal secretions, rapid shallow breathing, orthopnea, accessory respiratory muscle use, and hypercapnia with respiratory acidosis. Hypoxemia is a late sign observed immediately before respiratory failure.
Triggers and Risk Factors
Common Precipitants
Several triggers may precipitate myasthenic crisis. In approximately 30–40% of episodes, no clear inciting factor is identified.
- Infection: The most common trigger, especially bronchopulmonary infections (pneumonia, bronchitis, upper respiratory infections); urinary tract infections and sepsis are also important
- Medication changes: Rapid withdrawal or dose reduction of immunosuppressive therapy; initiation or large dose increases of corticosteroids (steroid dip in up to 15% of patients within 10 days)
- Surgery: Including thymectomy, cardiac surgery, and other major procedures
- Drugs that worsen MG: See warning box below
- Excessive cholinesterase inhibitor dosing: May elicit cholinergic crisis with depolarization blockade
- Pregnancy and puerperium: Exacerbations are more common during the first and third trimesters or postpartum
- Physiologic stress: Trauma, emotional distress, extreme temperatures, thyroid dysfunction
Patient Risk Factors
- History of prior myasthenic crisis
- Early course of generalized MG (first 2–3 years)
- Thymoma-associated MG
- MuSK antibody-positive MG (prominent bulbar and respiratory involvement)
- Severe generalized disease (MGFA Class IV–V)
- Prominent oropharyngeal weakness
Drugs That Can Precipitate Myasthenic Crisis
- High risk — avoid: Botulinum neurotoxins, D-penicillamine, telithromycin (boxed warning for MG)
- Antibiotics: Aminoglycosides (gentamicin, tobramycin), fluoroquinolones (ciprofloxacin, moxifloxacin, levofloxacin — FDA black box warning), macrolides (azithromycin, erythromycin)
- Cardiovascular: Beta-blockers (propranolol, atenolol, metoprolol), Class IA antiarrhythmics (procainamide, quinidine), calcium channel blockers
- Anesthetic agents: Succinylcholine (unpredictable response), non-depolarizing neuromuscular blocking agents (markedly increased sensitivity; use ¼–½ dose)
- Oncologic: Immune checkpoint inhibitors (nivolumab, pembrolizumab, ipilimumab — can cause de novo MG or exacerbate preexisting disease)
- Other: IV magnesium (all patients), oral magnesium (in renal failure), quinine, chloroquine/hydroxychloroquine, iodinated contrast agents (older formulations)
- Corticosteroids: Low risk, but transient worsening (steroid dip) may occur within 10 days of initiation or dose increase — particularly dangerous in patients with moderate-to-severe bulbar or respiratory weakness
Myasthenic Crisis vs. Cholinergic Crisis
Distinguishing myasthenic crisis from cholinergic crisis is a classic clinical question, although cholinergic crisis has become uncommon in modern practice due to reduced reliance on high-dose cholinesterase inhibitors. Both conditions present with worsening weakness and respiratory failure, but the underlying mechanisms and management differ fundamentally.
| Feature | Myasthenic Crisis | Cholinergic Crisis |
|---|---|---|
| Mechanism | Undertreated MG — insufficient neuromuscular transmission due to autoimmune endplate dysfunction | Overtreatment with cholinesterase inhibitors — depolarization blockade from excessive acetylcholine |
| Pupils | Normal or mydriatic | Miotic (constricted) |
| Secretions | Normal or mildly increased (from bulbar weakness) | Profuse — salivation, lacrimation, bronchorrhea (SLUDGE: Salivation, Lacrimation, Urination, Defecation, GI cramping, Emesis) |
| Fasciculations | Absent | Present (nicotinic effect) |
| Muscarinic signs | Absent | Bradycardia, miosis, diarrhea, diaphoresis, bronchospasm |
| Heart rate | Normal or tachycardic (from respiratory distress) | Bradycardic (parasympathetic excess) |
| Pyridostigmine history | Often subtherapeutic or recently reduced | Excessive doses or recent increase |
| Management | Continue pyridostigmine (hold during intubation); initiate PLEX or IVIg | Immediately discontinue all cholinesterase inhibitors; atropine for muscarinic symptoms |
Practical Approach to Differentiating the Two Crises
- The edrophonium (Tensilon) test was historically used to differentiate the two types — improvement indicated myasthenic crisis, while worsening indicated cholinergic crisis
- Edrophonium was discontinued by the FDA in 2018 and is no longer recommended in the acute setting due to the risk of precipitating severe respiratory failure and a high rate of false positives
- In practice, the distinction is often moot: both crises require withdrawal of cholinesterase inhibitors, airway protection, and ICU management
- The safest approach is to hold all cholinesterase inhibitors, secure the airway, and treat as a myasthenic crisis with rescue immunotherapy — pyridostigmine can be cautiously reintroduced after the patient is stabilized
- True cholinergic crisis is rare in current practice; most acute respiratory decompensation in MG patients represents myasthenic crisis
Respiratory Monitoring
Bedside Pulmonary Function Tests
Serial measurement of pulmonary function is the cornerstone of monitoring patients with impending or manifest myasthenic crisis. The three key parameters are:
- Forced vital capacity (FVC): Measures total volume of air that can be forcibly exhaled; reflects both inspiratory and expiratory muscle strength. Normal is approximately 60–70 mL/kg.
- Negative inspiratory force (NIF): Also called maximal inspiratory pressure (MIP); measures the negative pressure generated during a maximal inspiratory effort against an occluded airway. Normal is more negative than –70 cmH2O.
- Maximal expiratory pressure (MEP): Measures cough strength and ability to clear secretions. Normal is >80 cmH2O.
The 20/30/40 Rule — Thresholds for ICU Escalation
- FVC <20 mL/kg — indicates significant respiratory muscle weakness; consider ICU transfer
- NIF weaker than –30 cmH2O (i.e., less negative, closer to zero) — inspiratory muscle failure
- MEP <40 cmH2O — impaired cough and secretion clearance
- These values guide level of care (ICU vs. step-down vs. floor), not the decision to intubate
- Trending is more important than single values — a declining trajectory (e.g., FVC dropping from 30 to 22 mL/kg over hours) is more alarming than a stable low value
- Measure every 2–4 hours in patients with impending crisis; every 4–6 hours once stable in the ICU
- Measurements require patient cooperation and effort — bulbar weakness may limit reliability due to air leak around the mouthpiece
Limitations of Pulse Oximetry and ABG
Pulse oximetry and arterial blood gases are inadequate for early detection of neuromuscular respiratory failure. Oxygen saturation may remain normal until FVC drops below 15 mL/kg because hypoxemia is a late finding that occurs shortly before respiratory arrest. Similarly, CO2 retention (hypercapnia) may not be evident until the patient is in extremis. Reliance on these measures alone creates a false sense of security.
Intubation and Ventilator Management
Indications for Intubation
The decision to intubate should be based on the clinical trajectory and not solely on a single pulmonary function value. Elective, planned intubation is always preferable to emergency intubation.
- Progressive respiratory distress with increasing tachypnea and declining FVC despite treatment
- FVC <15 mL/kg or a >50% decline from baseline
- NIF weaker than –20 cmH2O
- Severe bulbar dysfunction with inability to protect the airway, weak cough, and difficulty clearing secretions
- Progressive hypercapnia (PCO2 >50 mmHg) on arterial blood gas
- Chest radiograph showing significant atelectasis or aspiration
- Clinical signs of fatigue, paradoxical breathing, or accessory muscle use
Airway Management Considerations
Intubation Pearls in Myasthenic Crisis
- Avoid succinylcholine: MG patients have reduced acetylcholine receptors and may be resistant to succinylcholine (requiring 2–3× normal dose), but the response is unpredictable and prolonged paralysis can occur
- Non-depolarizing agents: Patients are markedly sensitive; use ¼ to ½ the standard dose of rocuronium or vecuronium if required
- Sugammadex: Preferred reversal agent for rocuronium — superior to neostigmine in MG patients for reversal of neuromuscular blockade
- Consider intubation without neuromuscular blockade: Many MC patients have sufficient muscle weakness that direct laryngoscopy with sedation alone is feasible
- Noninvasive ventilation (NIV/BiPAP): May be trialed in cooperative patients with intact bulbar function; initial NIV use is associated with shorter total ventilatory support (median 4 days vs. 9 days in those directly intubated) and prevented reintubation in 70% of patients in selected series
- Avoid respiratory depressants: Minimize opioids and benzodiazepines; if sedation is required, use low-dose propofol or dexmedetomidine
Ventilator Settings
Initial ventilator management typically uses assist-control or pressure-support ventilation. Lung-protective strategies (tidal volumes of 6–8 mL/kg of ideal body weight) should be employed to minimize ventilator-induced lung injury. PEEP of 5–8 cmH2O is generally appropriate. The goal is to rest the respiratory muscles while rescue immunotherapy takes effect.
Rescue Immunotherapy: IVIg vs. PLEX
Plasma exchange (PLEX) and intravenous immunoglobulin (IVIg) are the two principal rescue therapies for myasthenic crisis. Both are effective, and the choice often depends on practical considerations, antibody subtype, and institutional experience.
| Parameter | Plasma Exchange (PLEX) | IVIg |
|---|---|---|
| Mechanism | Directly removes circulating pathogenic antibodies, complement, and cytokines | Modulates immune response via multiple mechanisms (Fc receptor blockade, complement modulation, anti-idiotypic effects) |
| Standard regimen | 5 exchanges of 1.0–1.5 plasma volumes on alternate days over 10–14 days | 2 g/kg total dose divided over 2–5 days (e.g., 0.4 g/kg/day × 5 days) |
| Onset of improvement | Often after the 3rd exchange (days 5–7) | Typically 5–7 days after initiation |
| Duration of benefit | 3–4 weeks (up to 12 weeks in some patients) | 4–12 weeks |
| Efficacy in AChR MG | ~65% of patients improve | ~65% of patients improve |
| Efficacy in MuSK MG | Preferred — more effective than IVIg (MuSK IgG4 antibodies are directly removed) | Less effective; IVIg does not efficiently target IgG4 subclass antibodies |
| Vascular access | Requires large-bore catheter (central venous preferred; peripheral access when feasible to reduce complications) | Standard peripheral IV access |
| Key complications | Hypotension, catheter-related (thrombosis, infection, pneumothorax), hypocalcemia (from citrate), coagulopathy | Headache, fever, aseptic meningitis, anaphylaxis (IgA-deficient patients), thromboembolic events, renal dysfunction (sucrose-containing formulations) |
| Contraindications | Hemodynamic instability, active sepsis, severe coagulopathy | IgA deficiency with anti-IgA antibodies, hyperviscosity syndromes, recent thrombotic events |
| Drug interactions | Removes IVIg if given concurrently; may reduce levels of other drugs | May interfere with live vaccines for up to 3 months |
| Advantages | May have slightly faster onset; preferred in MuSK MG; can combine with complement inhibitors | Easier to administer; no specialized equipment; better for pediatric patients and those with poor vascular access |
Head-to-Head Evidence: IVIg vs. PLEX
- The Barth et al. (2011) randomized, evaluator-masked trial of 84 patients with worsening MG found comparable efficacy between IVIg (1 g/kg × 2 days) and PLEX (5 exchanges) at day 14, with similar responder rates (~55–65%), persistence of benefit, and tolerability
- Baseline disease severity was the only predictor of treatment response in both groups
- A 2023 systematic review and meta-analysis confirmed no significant difference in overall efficacy but noted a trend toward faster improvement with PLEX, particularly at 2 weeks
- For MuSK MG, retrospective data consistently support PLEX over IVIg, likely because PLEX directly removes pathogenic IgG4 antibodies
- In clinical practice, IVIg is more commonly chosen for initial rescue due to ease of administration, particularly in centers without access to apheresis services or in patients with poor vascular access
- There is no benefit to combining IVIg and PLEX simultaneously; PLEX will remove the administered IVIg
- If the first-line rescue therapy fails after an adequate course, switching to the alternative modality is a standard approach
Emerging Rescue Therapies
Several newer biological agents are being studied as adjunctive rescue therapies in myasthenic crisis:
- FcRn inhibitors (efgartigimod): Case series report rapid improvement when added to standard rescue therapy in both manifest and impending crisis; onset within 1–2 weeks; useful as a bridge or adjunct
- Complement inhibitors (eculizumab): Case reports describe rapid and profound improvement in refractory crisis; the ELEVATE study demonstrated reduced frequency of exacerbation and crisis with long-term eculizumab therapy
- These novel agents are not yet established as first-line rescue therapies but represent important options for refractory cases
Corticosteroids in Crisis
Corticosteroids are the backbone of long-term MG immunotherapy, but their use during acute crisis requires careful consideration.
The Steroid Dip
Initiation of prednisone or large dose increases may cause transient exacerbation of MG weakness (steroid dip) in up to 15% of patients, typically within 10 days. This can be catastrophic in patients already in or near crisis. The risk is highest in patients with moderate-to-severe bulbar or respiratory weakness.
Practical Approach
- Do not start high-dose steroids during active crisis without first initiating PLEX or IVIg — the rescue therapy provides a protective buffer against steroid-induced exacerbation
- For patients already intubated, corticosteroids can be started or continued at therapeutic doses, as the patient is on ventilatory support
- For impending crisis, initiate PLEX or IVIg first, then begin prednisone at a moderate dose (20–40 mg/day) with cautious escalation
- For patients already on chronic corticosteroids, do not abruptly discontinue them during crisis — maintain at least the pre-crisis dose to avoid adrenal insufficiency and MG flare
- IV methylprednisolone (1 g/day for 3–5 days) may be used in severe cases, but always in conjunction with ongoing rescue therapy and ventilatory support
ICU Management
Beyond respiratory support and rescue immunotherapy, comprehensive ICU care is essential for favorable outcomes in myasthenic crisis.
Infection Prevention and Treatment
- Infection is the most common trigger for crisis and the leading cause of death in MC — vigilant infection surveillance is critical
- Obtain blood cultures, respiratory cultures, and urinalysis early; treat empirically if clinical suspicion is high
- Avoid aminoglycosides and fluoroquinolones; preferred antibiotics include penicillins, cephalosporins, carbapenems, and trimethoprim-sulfamethoxazole
- Aspiration pneumonia is common due to bulbar weakness — maintain head-of-bed elevation ≥30° and aggressive oral care
DVT Prophylaxis
- All intubated MG patients should receive pharmacologic DVT prophylaxis (subcutaneous heparin or enoxaparin) plus sequential compression devices
- Risk is increased by immobility, central venous catheter placement for PLEX, and dehydration
Nutrition
- Early enteral nutrition is preferred over parenteral nutrition when feasible
- Nasogastric or orogastric tube feeding if bulbar weakness prevents safe oral intake
- Monitor for ileus and gastroparesis, which may occur with immobility and autonomic dysfunction
Physical and Respiratory Therapy
- Early mobilization when hemodynamically stable to prevent deconditioning, atelectasis, and DVT
- Chest physiotherapy and incentive spirometry to prevent atelectasis
- Range-of-motion exercises throughout ventilator course
Psychosocial Support
- Patients with MC are often fully conscious and alert during intubation — this is a source of significant anxiety
- Ensure appropriate anxiolysis, communication tools, and family involvement in care
- Avoid oversedation, which confounds neurologic assessment
Weaning from Mechanical Ventilation
Even with expeditious administration of rescue immunotherapy, endplate structure and function require time to normalize. The mean duration of intubation in myasthenic crisis is 12–13 days, with an optimal extubation window between days 7 and 12.
Extubation Readiness Criteria
- FVC >15 mL/kg (some experts use >20 mL/kg for greater safety margin)
- NIF better than –30 cmH2O (more negative values indicate stronger inspiratory effort)
- Adequate cough strength and ability to clear secretions independently
- Improved bulbar function — ability to handle oral secretions, swallow safely
- Improved neck flexion strength (surrogate for oropharyngeal muscle function)
- Successful spontaneous breathing trial (SBT) — typically 30–120 minutes on minimal pressure support or T-piece
- Resolution of the precipitating trigger (especially infection)
Predictors of Prolonged Ventilation (>14 days)
| Risk Factor | Clinical Significance |
|---|---|
| Age >50 years | Strongest predictor of prolonged intubation |
| Late-onset MG | Associated with more comorbidities and slower recovery |
| Peak FVC <25 mL/kg on post-intubation days 1–6 | Reflects severity of respiratory muscle involvement |
| Serum bicarbonate ≥30 mmol/L | Suggests chronic respiratory compensation (metabolic alkalosis) |
| Pneumonia or atelectasis | Complicates weaning; OR 3.13 for prolonged ventilation |
| >3 medical comorbidities | OR 2.99 for prolonged ventilation |
| MGFA Class IVb–V before crisis | Higher baseline severity predicts slower recovery |
Extubation failure (requiring reintubation within 48–72 hours) is most commonly associated with weak cough, inadequate airway clearance, older age, and pulmonary complications. Tracheostomy should be considered if ventilator liberation is not anticipated within 2–3 weeks.
Perioperative Management of MG Patients
Patients with MG are at increased risk of perioperative myasthenic crisis and prolonged postoperative ventilation. A structured approach minimizes complications.
Preoperative Optimization
- Optimize MG control before elective surgery; target minimal manifestation status
- Preoperative FVC >70% predicted generally indicates adequate respiratory reserve for extubation at end of surgery
- Preoperative PLEX or IVIg for patients with moderate-to-severe bulbar or generalized weakness, particularly before thymectomy
- Preoperative IVIg is unnecessary for patients with well-controlled MG undergoing thymectomy
- Minimize prednisone dose before surgery (ideally ≤20 mg/day) to promote wound healing
Intraoperative Considerations
- Quantitative neuromuscular monitoring (train-of-four) is essential
- Avoid or reduce dose of non-depolarizing neuromuscular blocking agents (¼–½ standard dose)
- Avoid succinylcholine (unpredictable pharmacodynamics)
- Use sugammadex for reversal of rocuronium/vecuronium — superior to neostigmine in MG patients; may reduce postoperative pneumonia and crisis risk
- Use short-acting anesthetic agents when possible
- Maintain normothermia and avoid excessive fluids
Postoperative Monitoring
- Plan for postoperative ICU or step-down observation with serial FVC and NIF monitoring
- Restart oral pyridostigmine as soon as the patient can take oral medications; IV neostigmine can be used as a bridge (dose: approximately 1/30th of oral pyridostigmine dose)
- Resume immunosuppressive medications at pre-operative doses
- Aggressively manage postoperative pain without excessive opioids — regional anesthesia techniques are preferred
Medication Management During Crisis
Medications to Hold
- Cholinesterase inhibitors (pyridostigmine): Hold during intubation — they increase bronchial secretions and complicate airway management; also, the distinction from cholinergic crisis mandates initial cessation
- Medications that worsen MG: Review all current medications and discontinue any known to worsen neuromuscular transmission (see warning box above)
Medications to Continue or Initiate
- Corticosteroids: Continue at pre-crisis dose if already on chronic therapy; do not abruptly discontinue (risk of adrenal crisis and MG flare)
- Nonsteroidal immunosuppressants (azathioprine, mycophenolate, tacrolimus): Continue at the same dose unless there is a specific reason to hold (e.g., active sepsis, leukopenia)
- Rescue immunotherapy: Initiate PLEX or IVIg as early as possible — do not delay for diagnostic workup
- Stress-dose steroids: Provide hydrocortisone 50–100 mg IV every 8 hours if the patient has been on chronic corticosteroids and is critically ill or undergoing a procedure
Restarting Pyridostigmine
Once the patient is stabilized and ready for ventilator weaning, pyridostigmine can be cautiously restarted at a low dose (30 mg every 4–6 hours via nasogastric tube or orally) and titrated based on response. Monitor for cholinergic side effects (excessive secretions, bradycardia, GI cramping), which can impair weaning.
Discharge Planning and Crisis Prevention
Inpatient-to-Outpatient Transition
- Establish or adjust long-term immunotherapy (prednisone, nonsteroidal immunosuppressant, or biological agent) to sustain the transient improvement from PLEX or IVIg
- For patients unsuitable for corticosteroids, intermediate-term options include maintenance IVIg, subcutaneous immunoglobulin, FcRn antagonists, or complement inhibitors to bridge to the delayed benefit of nonsteroidal immunosuppressants
- Ensure close neurology follow-up within 1–2 weeks of discharge
- Optimize thymectomy timing for eligible patients (nonthymomatous AChR MG, age 18–50, within first 2 years of disease)
Patient Education
- Provide a wallet card or medical alert bracelet listing MG diagnosis and medications to avoid
- Ensure patients carry the MGFA emergency management card for first responders
- Educate on early warning signs of crisis: increasing dyspnea, orthopnea, difficulty swallowing, inability to hold up the head, or worsening voice quality
- Instruct to seek emergency care immediately if these symptoms develop — do not wait for the next scheduled appointment
Strategies to Prevent Recurrent Crisis
- Adherence to immunotherapy: Non-compliance with medications is a common precipitant
- Infection prevention: Annual influenza and pneumococcal vaccination; prompt treatment of respiratory infections
- Medication review: All healthcare providers must be aware of the MG diagnosis and the list of contraindicated medications
- Avoid abrupt medication changes: Gradual tapering of immunosuppression under close monitoring
- Perioperative planning: Any surgery should involve neurology consultation and consideration of preoperative rescue therapy
- Steroid initiation strategy: When starting corticosteroids, use a low-dose escalation approach or provide PLEX/IVIg prophylaxis for patients at high risk of steroid dip
References
- Claytor B, Cho SM, Li Y. Myasthenic crisis. Muscle Nerve. 2023;68(1):8-19.
- Neumann B, Angstwurm K, Mergenthaler P, et al. Myasthenic crisis demanding mechanical ventilation: a multicenter analysis of 250 cases. Neurology. 2020;94(3):e299-e313.
- Barth D, Nabavi Nouri M, Ng E, Nwe P, Bril V. Comparison of IVIg and PLEX in patients with myasthenia gravis. Neurology. 2011;76(23):2017-2023.
- Juel VC. Autoimmune myasthenia gravis. Continuum (Minneap Minn). 2025;31(5, Muscle and Neuromuscular Junction Disorders):1270-1302.
- Cabrera Serrano M, Rabinstein AA. Causes and outcomes of acute neuromuscular respiratory failure. Arch Neurol. 2010;67(9):1089-1094.
- Narayanaswami P, Sanders DB, Wolfe G, et al. International consensus guidance for management of myasthenia gravis: 2020 update. Neurology. 2021;96(3):114-122.
- Zinman L, Ng E, Bril V. IV immunoglobulin in patients with myasthenia gravis: a randomized controlled trial. Neurology. 2007;68(11):837-841.
- Skeie GO, Apostolski S, Evoli A, et al. Guidelines for treatment of autoimmune neuromuscular transmission disorders. Eur J Neurol. 2010;17(7):893-902.
- Hong Y, Gao L, Huang SQ, et al. Efgartigimod as a fast-acting add-on therapy in manifest and impending myasthenic crisis: a single-center case series. J Neuroimmunol. 2024;395:578431.
- Vinciguerra C, Bevilacqua L, Toriello A, et al. Starting eculizumab as rescue therapy in refractory myasthenic crisis. Neurol Sci. 2023;44(10):3707-3709.
- Gamez J, Salvado M, Carmona F, et al. Intravenous immunoglobulin to prevent myasthenic crisis after thymectomy and other procedures can be omitted in patients with well-controlled myasthenia gravis. Ther Adv Neurol Disord. 2019;12:1756286419864497.
- Nowak RJ, Habib AA, Klink AJ, et al. US clinical practice experience with eculizumab in myasthenia gravis: acute clinical events and healthcare resource utilization. Drugs Real World Outcomes. 2024;11(4):593-601.